Angiozyme
Angiozyme, also known as RPI.4610, is an advanced anti-angiogenic ribozyme that has garnered significant attention in the field of oncology, specifically for the treatment of kidney cancer. Ribozymes are RNA molecules that have catalytic activity, and in the context of Angiozyme, it has been tailored to prevent angiogenesis, the process of new blood vessel formation. By inhibiting angiogenesis, the growth and progression of tumors can potentially be halted since tumors rely on new blood vessels for their growth and metastasis.
Overview[edit | edit source]
- Type: Anti-angiogenic ribozyme
- Other Names: RPI.4610
- Main Use: Treatment of kidney cancer
Mechanism of Action[edit | edit source]
Angiozyme operates by interfering with the vascular endothelial growth factor (VEGF) receptor. The VEGF receptor is integral in the process of angiogenesis. By inhibiting this receptor, Angiozyme might halt the growth of new blood vessels that tumors require for nourishment and growth.
Clinical Studies[edit | edit source]
Extensive studies and clinical trials are being conducted to determine the efficacy of Angiozyme in treating kidney cancer. Early observations indicate:
- Efficacy: The potential of halting or slowing down the growth of kidney tumors.
- Side Effects: Preliminary tests have suggested that Angiozyme exhibits no significant side effects, which can make it a promising agent in cancer therapy, provided its therapeutic efficacy is conclusively demonstrated.
Drug Classification[edit | edit source]
Angiozyme falls under the drug families of:
- VEGF receptor inhibitors: Drugs that target the VEGF receptors, inhibiting their action.
- Angiogenesis inhibitors: A broader class of drugs designed to curtail the growth of new blood vessels.
Future Prospects[edit | edit source]
While the current findings on Angiozyme are promising, further long-term studies are required to fully understand its potential and limitations. If proven effective, it can be a valuable addition to the arsenal of drugs available for kidney cancer treatment, especially given its reportedly minimal side effects.
See also[edit | edit source]
External links[edit | edit source]
- Angiozyme entry in the public domain NCI Dictionary of Cancer Terms
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD